Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · December 11, 2021

Guselkumab Shows Consistent Safety Profile With Up to 5 Years of Continuous Treatment

Journal of the American Academy of Dermatology

 

Additional Info

Journal of the American Academy of Dermatology
Consistent safety profile with up to five years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
J Am Acad Dermatol 2021 Nov 16;[EPub Ahead of Print], A Blauvelt, TF Tsai, RG Langley, M Miller, YK Shen, Y You, YW Yang, KA Papp, L Puig

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading